CUPERTINO, Calif., March 1, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the Cowen and Company 31st Annual Healthcare Conference on Monday, March 7 at 1:00 pm Eastern Time. The conference is being held at the Marriott Copley […]
DURECT to Present at Cowen and Company Health Care Conference Read More »
CUPERTINO, Calif., Feb. 24, 2011 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, March 2, 2011 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo:
DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call Read More »
CUPERTINO, Calif., Feb. 9, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb shoulder clinical trial conducted by Nycomed of POSIDUR(TM) (also known as SABER(TM)-bupivacaine or Optesia(TM) in the E.U.), a proprietary product under development for the treatment of post-surgical pain, and the amendment of the Company’s
Covers an Animal Health Application CUPERTINO, Calif., Feb. 8, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today reported that its collaborator, CreoSalus, Inc., has launched commercial sales of its Food and Drug Administration (FDA) approved product known as SucroMate(TM) Equine, an injectable animal health drug utilizing DURECT’s SABER(TM) technology to deliver the peptide
DURECT Announces Launch of First FDA Approved SABER(TM)-Injectable Peptide Product Read More »
CUPERTINO, Calif., Feb. 7, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Monday, February 14 at 9:30 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)
DURECT to Present at the BIO CEO & Investor Conference Read More »
CUPERTINO, Calif., Jan. 27, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today reported that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for REMOXY(R) by King Pharmaceuticals, Inc. (NYSE: KG) and the PDUFA goal date is June 23, 2011. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) REMOXY, based on
REMOXY(R) New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 Read More »
CUPERTINO, Calif., Dec. 27, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King has resubmitted a New Drug Application (NDA) for REMOXY(R) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter
REMOXY(R) New Drug Application Resubmitted Read More »
CUPERTINO, Calif., Nov. 22, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) and Joe Stauffer (Chief Medical Officer) will be presenting at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1 at 10:30 a.m. Eastern Time. The conference is being held at the
DURECT to Present at the Piper Jaffray 2010 Health Care Conference Read More »
CUPERTINO, Calif., Nov. 8, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Credit Suisse 2010 Healthcare Conference on Friday, November 12 at 8:30 a.m. Pacific Time. The conference is being held at the Arizona Biltmore in Phoenix. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) (Logo:
DURECT to Present at the Credit Suisse 2010 Healthcare Conference Read More »
CUPERTINO, Calif., Nov. 3, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2010. Total revenues were $8.1 million for the three months ended September 30, 2010 compared to $8.4 million for the three months ended September 30, 2009; revenues in the 2009 period
DURECT Corporation Announces Third Quarter 2010 Financial Results Read More »
